Search Results - collaboration+sought+%3e+licensing

1105 Results

Sort By:

Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images. Description of Technology: The present disclosure generally relates a method of automatically...

Published: 3/11/2026 | Inventor(s): Wathudurage De Silva, Catherine Cukras

Keywords(s):

Category(s): Application > Software / Apps, TherapeuticArea, TherapeuticArea > Ear, Nose, & Throat, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases. Description of Technology: Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases...

Published: 3/11/2026 | Inventor(s): S. Patricia Becerra, Rolf Swenson, Natarajan Raju, Alexandra Bernardo-Colon, Carolyn Woodroofe, Burchelle Blackman

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Humanized 40H3 Antibody

Summary: The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR. Description of Technology: Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have...

Published: 2/5/2026 | Inventor(s): David Fitzgerald, Antonella Antignani, Robert Sarnovsky

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Humanized Monoclonal Antibodies Specific Against Human Soluble Tissue Factor (hsTF) as Diagnosis, Prevention and Therapeutic Agents for Thrombosis

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel humanized monoclonal antibody (58B3) that selectively targets a newly identified soluble Tissue Factor (sTF) to diagnose, prevent and treat pathological thrombosis associated with inflammation, viral/bacterial infection, sepsis and cancer...

Published: 2/11/2026 | Inventor(s): Zheng-gang Liu, Swati Choksi, PeiXing Wan

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Diagnostics, Application > Therapeutics

Combination PDL1 and TGF Beta Blockade in Patients with HPV-Associated Malignancies

Summary: The National Cancer Institute (NCI) seeks collaborations and licensees for a method to block PD-L1 and TGF-beta for the treatment of HPV-associated malignancies. Description of Technology: Advanced or relapsed human papillomavirus (HPV)-associated cancers are incurable and many of these diseases do not have a standard second line therapy....

Published: 11/26/2025 | Inventor(s): Julius Strauss, James Gulley, Christian Hinrichs

Keywords(s):

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein

Summary: The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types. Description of Technology: Many...

Published: 9/29/2025 | Inventor(s): Jeffrey Schlom, Kwong-Yok Tsang

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. Description...

Published: 9/29/2025 | Inventor(s): Jeffrey Schlom, Duane Hamilton, Claudia Palena, Renee Donahue

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines

Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2

Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291...

Published: 9/29/2025 | Inventor(s): Karl Pfeifer, Bjorn Knollmann

Keywords(s):

Category(s): TherapeuticArea > Rare/Neglected Diseases, Application > Research Materials, Collaboration Sought > Licensing

Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy

Summary: The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors. Description of Technology: TCR-T therapies, particularly those targeting patient-specific neoantigens, remain a promising approach to the treatment metastatic cancers....

Published: 8/25/2025 | Inventor(s): Steven Feldman, Steven Rosenberg, Drew Deniger

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor. Description of Technology: T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: ab (alpha...

Published: 8/25/2025 | Inventor(s): James Kochenderfer, Lauren Cutmore

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

1 2 3 4 5 6 7 8 9 10 ...